in the first quarter thanks to higher demand. It pulled in $20.7 billion in sales last quarter for profits of $2.30 per share. In an earnings release, the company said that sales of consumer products like Tylenol and Zyrtec rose nearly 10% as consumers stocked up on over-the-counter drugs to reduce fever and other symptoms associated with COVID-19.
Johnson & Johnson, which has a market cap of $387 billion, announced in March that it has chosen a leading vaccine candidate for the virus; it anticipates starting human trials by September of this year. Chief scientific officer Paul Stoffels told ABC’s “The Week” that the company is aiming to deliver
Я верю в лучшее
Drug pushers. Yrumps beloved Dow needs speculative hype
How awesome that some companies are making huge monies on this COVID19 thingy... 🤑
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: WSJ - 🏆 98. / 63 Lire la suite »